Frovatriptan for the prevention of postdural puncture headache

G. Bussone, V. Tullo, F. D'Onofrio, V. Petretta, M. Curone, F. Frediani, C. Tonini, S. Omboni

Research output: Contribution to journalArticlepeer-review


Efficacy of 5-day treatment with oral frovatriptan 2.5 mg/die for the prophylaxis of post-dural puncture headache (PDPH) was tested in 50 in-patients. A mild headache occurred in 7 (14%) patients for a total of 9 days (p <0.01 vs. no-PDPH). Most episodes of PDPH occurred in the first days of treatment (only 1 patient had headache at dismissal): 5 patients had only 1 episode, while 2 had headache for 2 consecutive days. No other symptoms were recorded. Occurrence of PDPH in a subgroup of 6 (12%) patients previously submitted to a diagnostic lumbar puncture was also examined: 4 of them reported a PDPH on the previous lumbar puncture in absence of triptans. In only 1 of these 4 patients PDPH recurred under treatment with frovatriptan. In conclusion, our non-randomized open-label study suggests efficacy of oral frovatriptan for PDPH prevention. These results need to be confirmed in a randomized, controlled, double-blind study.

Original languageEnglish
Pages (from-to)809-813
Number of pages5
Issue number7
Publication statusPublished - Jul 2007


  • Diagnostic lumbar puncture
  • Frovatriptan
  • Postdural puncture headache

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Frovatriptan for the prevention of postdural puncture headache'. Together they form a unique fingerprint.

Cite this